Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ESPR Esperion Therapeutics	$0.99 -2.6%	$0.97	$0.69 ▼ $3.94	$196.93M	0.67	4.91 million shs	4.00 million shs
FHTX Foghorn Therapeutics	$4.84 -0.4%	$4.37	$2.94 ▼ $10.25	$269.78M	3.05	142,780 shs	870,126 shs
TERN Terns Pharmaceuticals	$3.83 -4.3%	$3.35	$1.87 ▼ $11.40	$334.51M	-0.18	1.48 million shs	1.46 million shs
VRCA Verrica Pharmaceuticals	$0.52 -10.3%	$0.55	$0.38 ▼ $8.98	$48.34M	1.75	600,296 shs	3.89 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ESPR Esperion Therapeutics	0.00%	-7.14%	+16.29%	-31.00%	-55.24%
FHTX Foghorn Therapeutics	0.00%	+2.54%	+16.91%	+32.60%	-15.83%
TERN Terns Pharmaceuticals	0.00%	-1.79%	+22.76%	+38.77%	-43.76%
VRCA Verrica Pharmaceuticals	0.00%	-10.64%	+4.37%	+18.18%	-92.83%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ESPR Esperion Therapeutics	4.2776 of 5 stars	3.4	3.0	3.9	3.3	1.7	0.6
FHTX Foghorn Therapeutics	2.1026 of 5 stars	3.6	0.0	0.0	3.2	1.7	0.6
TERN Terns Pharmaceuticals	4.2023 of 5 stars	3.3	1.0	4.1	3.3	3.3	0.6
VRCA Verrica Pharmaceuticals	4.0299 of 5 stars	3.1	1.0	4.7	3.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ESPR Esperion Therapeutics	2.80	Moderate Buy	$7.00	604.51% Upside
FHTX Foghorn Therapeutics	3.13	Buy	$12.13	150.52% Upside
TERN Terns Pharmaceuticals	2.60	Moderate Buy	$15.63	307.96% Upside
VRCA Verrica Pharmaceuticals	2.20	Hold	$8.00	1,430.81% Upside

Current Analyst Ratings Breakdown

Latest VRCA, TERN, FHTX, and ESPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
5/15/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
5/14/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/14/2025	VRCA Verrica Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/13/2025	TERN Terns Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$26.00 ➝ $15.00
5/7/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
4/30/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
4/30/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/25/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/25/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/23/2025	FHTX Foghorn Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ESPR Esperion Therapeutics	$332.31M	0.59	$0.02 per share	41.35	($1.97) per share	-0.50
FHTX Foghorn Therapeutics	$22.60M	11.94	N/A	N/A	($0.82) per share	-5.90
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	$4.07 per share	N/A
VRCA Verrica Pharmaceuticals	$7.57M	6.39	N/A	N/A	($0.11) per share	-4.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ESPR Esperion Therapeutics	-$51.74M	-$0.80	N/A	N/A	N/A	-59.03%	-0.91%	-29.47%	8/11/2025 (Estimated)
FHTX Foghorn Therapeutics	-$86.62M	-$1.36	N/A	N/A	N/A	-342.23%	N/A	-27.28%	8/6/2025 (Estimated)
TERN Terns Pharmaceuticals	-$88.85M	-$1.09	N/A	N/A	N/A	N/A	-28.81%	-27.55%	8/4/2025 (Estimated)
VRCA Verrica Pharmaceuticals	-$76.58M	-$1.20	N/A	N/A	N/A	N/A	N/A	-145.63%	8/13/2025 (Estimated)

Latest VRCA, TERN, FHTX, and ESPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	FHTX Foghorn Therapeutics	-$0.30	-$0.30	N/A	-$0.30	$4.96 million	$5.95 million
5/13/2025	Q1 2025	VRCA Verrica Pharmaceuticals	-$0.14	-$0.10	+$0.04	-$0.10	$2.53 million	$3.44 million
5/8/2025	Q1 2025	TERN Terns Pharmaceuticals	-$0.29	-$0.26	+$0.03	-$0.26	N/A	N/A
5/6/2025	Q1 2025	ESPR Esperion Therapeutics	-$0.18	-$0.21	-$0.03	-$0.21	$54.97 million	$65.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ESPR Esperion Therapeutics	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VRCA Verrica Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ESPR Esperion Therapeutics	N/A	1.18	0.81
FHTX Foghorn Therapeutics	N/A	3.16	3.16
TERN Terns Pharmaceuticals	N/A	30.89	30.89
VRCA Verrica Pharmaceuticals	N/A	1.34	1.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ESPR Esperion Therapeutics	47.39%
FHTX Foghorn Therapeutics	61.55%
TERN Terns Pharmaceuticals	98.26%
VRCA Verrica Pharmaceuticals	42.45%

Insider Ownership

Company	Insider Ownership
ESPR Esperion Therapeutics	1.70%
FHTX Foghorn Therapeutics	7.58%
TERN Terns Pharmaceuticals	1.50%
VRCA Verrica Pharmaceuticals	54.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ESPR Esperion Therapeutics	200	198.20 million	194.83 million	Optionable
FHTX Foghorn Therapeutics	120	55.74 million	51.52 million	Optionable
TERN Terns Pharmaceuticals	40	87.34 million	86.03 million	Not Optionable
VRCA Verrica Pharmaceuticals	40	92.49 million	42.55 million	Optionable

VRCA, TERN, FHTX, and ESPR Headlines

Recent News About These Companies

Verrica Shareholder Sues Board Over FDA Approval Hurdle Claims

June 27 at 7:35 PM | news.bloomberglaw.comN

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Sees Significant Decline in Short Interest

June 18, 2025 | marketbeat.com

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of "Hold" by Brokerages

June 16, 2025 | marketbeat.com

Verrica Pharmaceuticals (NASDAQ:VRCA) Shares Up 0% - Here's Why

June 10, 2025 | marketbeat.com

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

May 28, 2025 | globenewswire.com

Verrica Pharmaceuticals Reports Record Q1 Revenue and Advancements in Pipeline

May 18, 2025 | msn.com

Verrica Pharmaceuticals, Inc. (VRCA) Q1 2025 Corporate Update Conference Call

May 13, 2025 | seekingalpha.com

Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates

May 13, 2025 | zacks.com

Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results

May 13, 2025 | globenewswire.com

6VRCA : Earnings Outlook For Verrica Pharmaceuticals

May 13, 2025 | benzinga.com

Verrica Pharmaceuticals to Host Q1 2025 Earnings Call and Corporate Update

May 11, 2025 | msn.com

Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025

May 7, 2025 | globenewswire.com

Verrica Pharmaceuticals CEO to Present at Citizens Life Sciences Conference

May 4, 2025 | msn.com

Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York

April 30, 2025 | globenewswire.com

Why Verrica Pharmaceuticals Inc.’s (VRCA) Stock Is Down 5.94%

April 9, 2025 | aaii.comA

Verrica Pharmaceuticals Reports Strong First-Quarter Growth for YCANTH

April 9, 2025 | msn.com

In face of U.S. stock market selloff, shares of West Chester firm are on the rise

April 8, 2025 | bizjournals.com

Verrica Pharmaceuticals experiences ‘strong demand-led growth’ for YCANTH in Q1

April 8, 2025 | markets.businessinsider.com

Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025

April 7, 2025 | markets.businessinsider.com

RBC Capital Sticks to Their Hold Rating for Verrica Pharmaceuticals (VRCA)

April 5, 2025 | markets.businessinsider.com

Verrica Pharmaceuticals Adds Dr. Gavin Corcoran to Board of Directors

April 3, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 AI Infrastructure Stocks With Strong Growth, Not Hype
By Chris Markoch | June 26, 2025
View 3 AI Infrastructure Stocks With Strong Growth, Not Hype
3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
By Jeffrey Neal Johnson | June 18, 2025
View 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
Top 3 Silver Picks to Watch as Bull Market Gains Steam
By Chris Markoch | June 18, 2025
View Top 3 Silver Picks to Watch as Bull Market Gains Steam
These 3 Stocks Are Buying Back Billions in Shares
By Leo Miller | June 3, 2025
View These 3 Stocks Are Buying Back Billions in Shares
D-Wave Goes International With South Korea Partnership
By Nathan Reiff | June 23, 2025
View D-Wave Goes International With South Korea Partnership

VRCA, TERN, FHTX, and ESPR Company Descriptions

Esperion Therapeutics NASDAQ:ESPR

$0.99 -0.03 (-2.59%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.00 +0.01 (+1.05%)

As of 06/27/2025 05:44 PM Eastern

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Foghorn Therapeutics NASDAQ:FHTX

$4.84 -0.02 (-0.41%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.84 0.00 (0.00%)

As of 06/27/2025 04:34 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Terns Pharmaceuticals NASDAQ:TERN

$3.83 -0.17 (-4.25%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$3.61 -0.22 (-5.74%)

As of 06/27/2025 07:58 PM Eastern

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Verrica Pharmaceuticals NASDAQ:VRCA

$0.52 -0.06 (-10.28%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.57 +0.05 (+8.88%)

As of 06/27/2025 05:50 PM Eastern

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time